Upadacitinib demonstrated long-term efficacy for the treatment of ankylosing spondylitis among patients who failed to respond to prior biologic therapy.
Patients with SLE have a higher prevalence of primary headaches vs those with RA or pSS, but similar percentages were found when comparing healthy controls.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback